[HTML][HTML] Immunotherapy for glioma: current management and future application
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …
Pilot trial of adoptive transfer of chimeric antigen receptor–transduced T cells targeting EGFRvIII in patients with glioblastoma
A deletion variant of epidermal growth factor receptor (EGFRvIII) is a known driver mutation
in a subset of primary and secondary glioblastoma multiforme. Adoptive transfer of …
in a subset of primary and secondary glioblastoma multiforme. Adoptive transfer of …
The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists
Humans consider themselves discrete autonomous organisms, but recent research is
rapidly strengthening the appreciation that associated microorganisms make essential …
rapidly strengthening the appreciation that associated microorganisms make essential …
Clinical use of dendritic cells for cancer therapy
Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …
Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination
Purpose: Patients with glioblastoma have less than 15-month median survival despite
surgical resection, high-dose radiation, and chemotherapy with temozolomide. We …
surgical resection, high-dose radiation, and chemotherapy with temozolomide. We …
Dendritic cell vaccination of glioblastoma: road to success or dead end
A Datsi, RV Sorg - Frontiers in Immunology, 2021 - frontiersin.org
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …
and remains a therapeutic challenge: even after multimodal therapy, median survival of …
Induction of CD8+ T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic …
H Okada, P Kalinski, R Ueda, A Hoji… - Journal of clinical …, 2011 - ascopubs.org
Purpose A phase I/II trial was performed to evaluate the safety and immunogenicity of a
novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic …
novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic …
Current concepts and management of glioblastoma
Glioblastoma is the most common malignant primary brain tumor in adults. Its often rapid
clinical course, with many medical and psychosocial challenges, requires a multidisciplinary …
clinical course, with many medical and psychosocial challenges, requires a multidisciplinary …
Blood brain barrier: a challenge for effectual therapy of brain tumors
Brain tumors are one of the most formidable diseases of mankind. They have only a fair to
poor prognosis and high relapse rate. One of the major causes of extreme difficulty in brain …
poor prognosis and high relapse rate. One of the major causes of extreme difficulty in brain …